Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain.

ABSTRACT: For the treatment of neurological diseases, achieving sufficient exposure to the brain parenchyma is a critical determinant of drug efficacy. The blood-brain barrier (BBB) functions to tightly control the passage of substances between the bloodstream and the central nervous system, and as such poses a major obstacle that must be overcome for therapeutics to enter the brain. Monoclonal antibodies have emerged as one of the best-selling treatment modalities available in the pharmaceutical market owing to their high target specificity. However, it has been estimated that only 0.1% of peripherally administered antibodies can cross the BBB, contributing to the low success rate of immunotherapy seen in clinical trials for the treatment of neurological diseases. The development of new strategies

SUBMITTER: Bajracharya R 

PROVIDER: S-EPMC8709416 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature